Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma In the article accompanying this editorial, Jensen et al 20 provide an update on the READ ...
Integration of Telemedicine Consultation Into a Tertiary Radiation Oncology Department: Predictors of Use, Treatment Yield, and Effects on Patient Population Using the scoping review methodology ...
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...
In the article that accompanies this editorial, Wu et al 36 observed that residential exposure to fine particulate matter was associated with higher breast cancer incidence using prospective data from ...
Large-Scale Pharmacogenomics Analysis of Patients With Cancer Within the 100,000 Genomes Project Combining Whole-Genome Sequencing and Medical Records to Inform Clinical Practice This open-label, ...
Combination Immunotherapy for Advanced Melanoma—How to Choose? The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated ...
Efficacy, Safety, Pharmacokinetics, and Immunogenicity of DRL-Trastuzumab Versus Herceptin in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: A Randomized Controlled Trial ...
Organ preservation has become an attractive alternative to surgery (total mesorectal excision [TME]) among patients with rectal cancer after neoadjuvant therapy who achieve a clinical complete ...
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...
UGT1A1 Testing for the Risk of Nanoliposomal Irinotecan–Related Toxicity Phase III trials that randomly assign patients to a control treatment (C), an experimental treatment (A), or a combination ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback